The shipment of unlicensed biological products for the experimental treatment of animals anywhere in or from the United States is prohibited without prior authorization by the Deputy Administrator, Veterinary Services (VS), Animal and Plant Health Inspection Service (APHIS), United States Department of Agriculture (USDA). Requests for authorization must be accompanied by information specified in the regulations, including information relevant to the product's effect on the environment. Additional safeguards and tests may be required for products which contain live organisms, prepared by conventional means or by using the new biotechnology.
The current regulations in the Code of Federal Regulations (CFR) 9, 103.3 contain widely-used provisions for the shipment of unlicensed biological products which are to serve in experiments on domestic animals for the purpose of evaluating such products. These products are shipped for various reasons, but mainly for field safety studies prior to licensing and release of the products for use in animals.
In accordance with the Virus-Serum-Toxin Act (VSTA), the term "ship" is used in its broadest sense. It means transport by any means from one place to another and is synonymous with delivering for shipment.
The following considerations have been developed by APHIS as suggested guidelines for applicants preparing to conduct experiments with new products derived from live, recombinant organisms intended for use as veterinary biologies.
For the purpose of licensing, veterinary biologics derived by recombinant DNA (rDNA) techniques or developed from hybridomas may be classified into three broad categories, according to the biological characteristics of the new products and safety aspects. This approach is wholly analogous to the one used in reviewing licensing requirements for conventionally prepared products. For particulars of these categories, see Table I • Vaccines containing live organisms modified by gene insertion or deletion
Category III:
• Vaccines using live vectors to carry r-derived foreign genes Genetically-engineered live biological products which fall under the regulatory jurisdiction of the VSTA cannot be moved from strict containment without review and approval by Veterinary Services, APHIS, USDA. Experiments not involving release into the environment, or those conducted under contained conditions may still be initiated with approval from the appropriate Institutional Biosafety Committee (IBC). These experiments would normally be conducted under stringent containment levels similar to biosafety levels 4 and 3 as described in Appendix G-III of the National Institutes of Health (NIH) Guidelines. Such studies would normally involve new recombinant-derived organisms that are not fully characterized.
The authorization procedures required for shipment of biological products and the guidelines for review of applications to conduct field trials with live products from categories II and III will be considered on a case-by-case basis. The controlled movement of biological products from physical containment to field situations will be accomplished in three stages: movement from maximum and controlled containment conditions (containment levels 4 and 3 respectively), to quarantined field conditions (containment level 2), restricted field tests (containment level 1) and, finally, unrestricted geographical distribution after a license has been issued.
Currently, certain experiments involving release into the environment of any organism containing recombinant DNA, as described in Section III-A of NIH Guidelines, require Recombinant DNA Advisory Committee (RAC) review and NIH and IBC approval before initiation. The Office of Recombinant DNA Activities (ORDA) has proposed to amend this review and approval procedure by permitting submission to another Federal agency which has jurisdiction for review and approval of the experiment. Once approved by that Federal agency, the experiment may proceed without the necessity for NIH review or approval. Thus, the shipment of product and the release from contained facilities will require APHIS authorization.
The maximum and controlled containment levels 4 and 3 are similar to the physical containment levels described as BL4 and BL3 in Appendix G-II of the NIH Guidelines. The removal of test animals from these physical containment levels would require APHIS approval.
In order to move from controlled containment level 3 to quarantined field testing level 2, the data generated at level 3 and the experiment must be evaluated by VS, which will prepare an abbreviated Environmental Assessment (EA) or employ a Decision Document to authorize the shipment and initiation of the study. The latter includes information on the biological properties and potential environmental effects of the parent and modified organisms. Requests for such authorization have to be submitted in accordance with the provisions of 9 CFR 103.3.
Each submission must contain the following information:
1. A letter of permission from the regulatory authority in each state involved.
2. A description of the product, serial numbers of product to be used, recommendations for use, and results of preliminary research conducted in containment, including: a) Characteristics of the modified organism compared to the parent organism.
b) Molecular biology of the modified organism, including source and function of the DNA sequence used to modify the organism; vector description; genetic stability and expression. c) Some of the physical and chemical factors which can affect survival, reproduction, and dispersal, such as host range characteristics, pathogenicity, infectivity, toxicity, and the likelihood of exchange of genetic information between the modified and parent organism. d) Satisfactory purity and safety test results for each serial of product to be used.
3. A proposed general plan covering the methods and procedures for evaluating the products and for maintaining records of the quantity of experimental product prepared, shipped, and used. In the event of unanticipated adverse effects of the modified organism, proposed methods of biological or physical control and retrieval should be included in this plan. 4. A tentative list of the names and addresses of the proposed recipients and quantity of experimental product which is to be shipped to each individual.
5. Copies of labels or label sketches with the statement "Notice! For Experimental Use Only -Not For Sale" or equivalent.
Restricted field trials studies will be conducted under quarantine conditions acceptable to the Deputy Administrator, VS, and where there is adequate evidence of biological and/or physical control of the recombinant-DNA organism. Note that each study in this category will be conducted only in quarantine facilities maintained as described in the proposals already approved by the Deputy Administrator. Facilities shall be maintained and operated in an appropriate way to prevent the dissemination of any communicable disease. Test facilities may be inspected by a Veterinary Medical Officer of VS to determine whether they comply with the following guidelines:
Physical requirements of the facility
Generally the facility should be located and constructed so as to prevent test animals from having physical contact with other animals outside the facility. The holding area should be of sufficient size to prevent overcrowding of animals in quarantine. The facilities should be constructed with materials which can withstand cleaning and disinfection. Doors, windows and other openings should be provided with screens to prevent birds and insects from entering. A safe and effective program will be required to control insects, ectoparasites, and avian and mammalian pests. Facility specifications shall comply with applicable Federal, state and local laws, and regulations relating to pollution control and the protection of the environment.
Sanitation and security
The applicant shall arrange for a water supply adequate for use in cleaning and disinfecting the facility. All feed and bedding used in the approved quarantine facility shall originate from an area not under quarantine and shall be stored in the test facility in a vermin-proof storage area. Facilities must be adequately equipped to incinerate, or effectively disinfect bedding and solid waste at the conclusion of the study.
Upon the death or destruction of test animals, the applicant shall arrange for the disposal of carcasses by procedures acceptable to the Deputy Administrator. Surviving animals can be slaughtered if there is evidence that organisms are no longer present, or pose no risk to the environment.
To permit and encourage research in field trials outside quarantine (level 1) with recombinant DNA-derived live vaccines, the Deputy Administrator of VS may authorize a person or firm to ship unlicensed biological products for the purpose of evaluation (treatment of a limited number of animals in different locations under open field conditions). Appropriate data must be submitted so that the agency can determine if the conditions of the proposed restricted field trials are adequate to prevent the spread of disease. Prior to authorizing use of the unlicensed product in limited field trials, the Deputy Administrator will require the applicant to provide information so that the agency can assess the product's impact on the environment, in compliance with the provisions of the National Environment Policy Act (NEPA) and USDA regulations and APHIS Guidelines implementing NEPA. Information needed for the EA concerns purpose and need; alternatives; affected environment; environmental consequences; and consultation with other agencies (Table II) .
The EA presents and discusses scientific data and other information relevant to field tests and trials conducted out of containment with an experimental recombinantderived biological product. It is intended to provide the general public with documentation of the Department's view of environmental effects which may be associated with the gathering of information in these limited field releases.
If it is concluded that restricted field studies would not have an adverse impact on the environment, the agency will publish its findings in the Federal Register, and the field trial may be initiated 30 days following publication.
The license applicant must submit all necessary information, including results from the restricted field trials, to demonstrate that the product is pure, safe, potent and efficacious. The agency will prepare an amended or supplemental EA and will announce in the Federal Register that the document is available and that USDA intends In summary, procedures have been developed to facilitate the movement of live genetically-engineered biological products from stringent containment levels through a series of both biological and physical contraints (Table III, a-d) . The purpose is to develop information required to conduct field trials and to support a product license application. The agency's policy is not to impede nor inhibit the commercialization of live products derived from the new biotechnology, but to ensure that field trials are conducted in accordance with NEPA requirements and that USDA-licensed veterinary biological products remain pure, safe, potent and efficacious. 
